About

High Court Notice To Centre

High Court Notice To Centre


Chandigarh, 10 May 2019: Issuing a notice of motion to the Union of India, the Punjab and Haryana High Court today stayed the operation of an order relaxing condition for the supply of buprenorphine combination drugs, allegedly enhancing in the process the menace of drug addiction.

 

Buprenorphine is a derivative of an opioid alkaloid and is a more potent and longer-lasting analgesic than morphine. The notice by the Bench of Chief Justice Krishna Murari and Justice Arun Palli came after petitioner Dr Paramjeet Singh Ranu through senior counsel AK Chopra and Aashutosh Jerath submitted the action would also result in incalculable harm and injury to public at large, especially “incredulous youth of the country”.

 

Jerath submitted that the permission was granted to a Mumbai-based firm to manufacture buprenorphine sublingual tablets for opioid de-addiction’. The permission was also granted for manufacturing new drug formulation buprenorphine and naloxone sublingual tablets for the treatment of patients with opioid dependence.

 

Jerath added it was intriguing to note that the relaxation in the condition having wide repercussions on mental health of the public at large was given ostensibly on the basis of representation by the Association of Psychiatrists. None of the other stakeholders, the State Health Departments, National Aids Control Authority, the State Drugs Controllers and independent experts in the field of psychiatry, was taken into confidence before relaxing the condition.The Tribune